Skip to main content

Table 2 Disability-related costs (direct and indirect). Elaborated from [1]

From: Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

Type of disease/type of cost EDSS 0
(€)
EDSS 1
(€)
EDSS 2
(€)
EDSS 3
(€)
EDSS 4
(€)
EDSS 5
(€)
EDSS 6
(€)
EDSS 7
(€)
EDSS 8–10
(€)
RRMS
direct
201 201 201 636 636 636 636 5708 5708
RRMS
indirect
1143 1143 1143 11,847 11,847 11,847 11,847 28,411 28,411
SPMS
direct
5331 5331 5331 18,894 18,894 18,894 18,894 9589 9589
SPMS
indirect
4096 4096 4096 31,559 31,559 31,559 31,559 64,948 64,948
  1. RRMS 0–6: only costs for co-medications. Not included the costs for DMTs and other disease management costs (e.g., administration, monitoring, etc.) considered in other calculation sections of the model. EDSS: expanded disability status scale. RRMS: relapsing-remitting multiple sclerosis. SPMS: secondary progressive multiple sclerosis. Direct costs include only the healthcare direct costs. The non-healthcare direct costs were included among the indirect costs